144 related articles for article (PubMed ID: 36046437)
1. Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type.
Maccaroni E; Lenci E; Agostinelli V; Cognigni V; Giampieri R; Mazzanti P; Di Pietro Paolo M; Bianchi F; Brugiati C; Belvederesi L; Pagliaretta S; Mandolesi A; Scarpelli M; Murrone A; Morgese F; Ballatore Z; Berardi R
Explor Target Antitumor Ther; 2021; 2(3):240-248. PubMed ID: 36046437
[TBL] [Abstract][Full Text] [Related]
2. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
3. The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
Sorscher S
Oncologist; 2018 Nov; 23(11):1266-1268. PubMed ID: 29866945
[TBL] [Abstract][Full Text] [Related]
4. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Sorscher S; Ansley K; Delaney SD; Ramkissoon S
Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
[TBL] [Abstract][Full Text] [Related]
5. Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study.
Sun S; Liu Y; Eisfeld AK; Zhen F; Jin S; Gao W; Yu T; Chen L; Wang W; Chen W; Yuan M; Chen R; He K; Guo R
Front Oncol; 2019; 9():550. PubMed ID: 31297337
[No Abstract] [Full Text] [Related]
6. Pancreatic cancer 'mismatch' in Lynch syndrome.
Hendifar AE; Larson BK; Rojansky R; Guan M; Gong J; Placencio V; Tuli R; Hitchins M
BMJ Open Gastroenterol; 2019; 6(1):e000274. PubMed ID: 31275582
[TBL] [Abstract][Full Text] [Related]
7. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
[TBL] [Abstract][Full Text] [Related]
8. Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review.
Hodges A; Sun K; Sheu TG; Bernicker EH
Front Oncol; 2023; 13():1193503. PubMed ID: 37901336
[TBL] [Abstract][Full Text] [Related]
9. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
Carethers JM; Stoffel EM
World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
[TBL] [Abstract][Full Text] [Related]
10. An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome.
Therkildsen C; Jensen LH; Rasmussen M; Bernstein I
Clin Exp Gastroenterol; 2021; 14():181-197. PubMed ID: 34079322
[TBL] [Abstract][Full Text] [Related]
11. A radiological complete response to pembrolizumab in a patient with metastatic upper urinary tract urothelial cancer and Lynch syndrome.
Oki R; Urasaki T; Ueki A; Inamura K; Komai Y; Takahashi S; Yonese J; Yuasa T
IJU Case Rep; 2023 Jan; 6(1):33-36. PubMed ID: 36605683
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
[TBL] [Abstract][Full Text] [Related]
13. Metastatic colorectal carcinoma mimicking primary ovarian carcinoma presenting as 'giant' ovarian tumors in an individual with probable Lynch syndrome: a case report.
Ongom PA; Odida M; Lukande RL; Jombwe J; Elobu E
J Med Case Rep; 2013 Jun; 7():158. PubMed ID: 23787146
[TBL] [Abstract][Full Text] [Related]
14. The influence of STK11 mutation on acquired resistance to immunotherapy in advanced non-small cell lung cancer with Lynch syndrome: a case report and literature review.
Long Y; Tang Y; Cai C; Yu M; Zhang M; Chen R; Huang M
Ann Palliat Med; 2021 Jun; 10(6):7088-7094. PubMed ID: 33832284
[TBL] [Abstract][Full Text] [Related]
15. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
[TBL] [Abstract][Full Text] [Related]
16. Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients.
Kiyozumi Y; Matsubayashi H; Horiuchi Y; Higashigawa S; Oishi T; Abe M; Ohnami S; Urakami K; Nagashima T; Kusuhara M; Miyake H; Yamaguchi K
Cancer Med; 2019 Sep; 8(12):5534-5543. PubMed ID: 31386297
[TBL] [Abstract][Full Text] [Related]
17. MLH1 Exon 12 Gene Deletion Leading to Lynch Syndrome: A Case Report.
Cui S; Zhang X; Zou R; Ye F; Wang Y; Sun J
Oncol Res Treat; 2021; 44(7-8):414-421. PubMed ID: 34091457
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and molecular characteristics of DNA mismatch repair deficient endometrial cancer in a Japanese hospital-based population.
Yamamoto A; Yamaguchi T; Suzuki O; Ito T; Chika N; Kamae N; Tamaru JI; Nagai T; Seki H; Arai T; Tachikawa T; Akagi K; Eguchi H; Okazaki Y; Ishida H
Jpn J Clin Oncol; 2021 Jan; 51(1):60-69. PubMed ID: 32844218
[TBL] [Abstract][Full Text] [Related]
19. A pathological complete response after immunotherapy with pembrolizumab for distal duodenal adenocarcinoma caused by Lynch syndrome: a case report.
Ikeda S; Hu Q; Natsugoe K; Harima T; Tanaka Y; Kinoshita I; Nonaka K; Nambara S; Nakanishi R; Nakanoko T; Ota M; Kimura Y; Oki E; Oda Y; Yoshizumi T
Int Cancer Conf J; 2023 Oct; 12(4):279-284. PubMed ID: 37577343
[TBL] [Abstract][Full Text] [Related]
20. Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants.
Patel SA; Longacre TA; Ladabaum U; Lebensohn A; Lin AY; Haraldsdottir S
Oncologist; 2018 Dec; 23(12):1395-1400. PubMed ID: 30072391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
